VWF/ADAMTS13 Ratio As a Potential Biomarker for Early Detection of Hepatocellular Carcinoma

Overview

Journal BMC Gastroenterol

Publisher Biomed Central

Specialty Gastroenterology

Date 2019 Oct 23

PMID 31638892

Citations 19

Authors

Hiroaki Takaya

Tadashi Namisaki

Mitsuteru Kitade

Kosuke Kaji

Keisuke Nakanishi

Yuki Tsuji

Naotaka Shimozato

Kei Moriya

Kenichiro Seki

Yasuhiko Sawada

Soichiro Saikawa

Shinya Sato

Hideto Kawaratani

Takemi Akahane

Ryuichi Noguchi

Masanori Matsumoto

Hitoshi Yoshiji

Affiliations

Soon will be listed here.

Abstract

Background: To investigate the von Willebrand factor to ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma (HCC) in cirrhosis.

Methods: Serum levels of alpha-fetoprotein, des-γ-carboxy prothrombin, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein (alpha-fetoprotein-L3%), vascular endothelial growth factor, and vascular endothelial growth factor receptor-2, as well as the plasma levels of von Willebrand factor antigen (von Willebrand factor: Ag) and ADAMTS13 activity (ADAMTS13:AC), were evaluated in 41 cirrhotic patients with HCC undergoing radiofrequency ablation and in 20 cirrhotic patients without HCC. The diagnostic accuracy of each biomarker was evaluated using the receiver operating characteristic curve analysis.

Results: The von Willebrand factor: Ag and von Willebrand factor: Ag/ADAMTS13:AC ratios were significantly higher in cirrhotic patients with HCC than in those without HCC (p < 0.05 and p < 0.01, respectively), whereas ADAMTS13:AC was significantly lower in those with HCC than those without HCC (p < 0.05). However, no relationship was observed between the von Willebrand factor: Ag/ADAMTS13:AC ratio and serum tumor markers such as alpha-fetoprotein, des-γ-carboxy prothrombin, and alpha-fetoprotein-L3%. Multivariate regression analysis identified von Willebrand factor: Ag/ADAMTS13:AC ratio and alpha-fetoprotein-L3% as significant factors of HCC development. Receiver operating characteristic analysis showed that the von Willebrand factor: Ag/ADAMTS13:AC ratio and alpha-fetoprotein-L3% had a better performance than alpha-fetoprotein, des-γ-carboxy prothrombin, alpha-fetoprotein-L3%, vascular endothelial growth factor, and vascular endothelial growth factor receptor-2, von Willebrand factor: Ag, and ADAMTS13:AC. The von Willebrand factor: Ag/ADAMTS13:AC ratio was exclusively correlated with tumor volume and stage as well as serum vascular endothelial growth factor levels.

Conclusions: The von Willebrand factor: Ag/ADAMTS13:AC ratio can potentially serve as a novel biomarker for early diagnosis of HCC in cirrhotic patients.

Citing Articles

ADAMTS13 Improves Hepatic Platelet Accumulation in Pyrrolizidine Alkaloids-induced Liver Injury.

Ji M, Chen Y, Ma Y, Li D, Ren J, Jiang H J Clin Transl Hepatol. 2025; 13(1):25-34.

PMID: 39801786 PMC: 11712092. DOI: 10.14218/JCTH.2024.00233.

Von Willebrand Factor Antigen Improves Risk Stratification for Patients with a Diagnosis of Resectable Hepatocellular Carcinoma.

Pereyra D, Mandorfer M, Santol J, Gregory L, Koeditz C, Ortmayr G Ann Surg Oncol. 2024; 31(10):6526-6536.

PMID: 38896229 DOI: 10.1245/s10434-024-15618-w.

Management of Portal Hypertension in Patients with Hepatocellular Carcinoma on Systemic Treatment: Current Evidence and Future Perspectives.

De Gaetano V, Pallozzi M, Cerrito L, Santopaolo F, Stella L, Gasbarrini A Cancers (Basel). 2024; 16(7).

PMID: 38611066 PMC: 11011056. DOI: 10.3390/cancers16071388.

The Perspectives of Platelet Proteomics in Health and Disease.

Chaudhary P, Upadhayaya S, Kim S, Kim S Biomedicines. 2024; 12(3).

PMID: 38540198 PMC: 10968484. DOI: 10.3390/biomedicines12030585.

Von Willebrand Factor as a Biomarker for Liver Disease - An Update.

Elhence A, Shalimar J Clin Exp Hepatol. 2023; 13(6):1047-1060.

PMID: 37975050 PMC: 10643510. DOI: 10.1016/j.jceh.2023.05.016.

References

Taketa K, Endo Y, SEKIYA C, Tanikawa K, Koji T, Taga H . A collaborative study for the evaluation of lectin-reactive alpha-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res. 1993; 53(22):5419-23. View

Edwards D, Handsley M, Pennington C . The ADAM metalloproteinases. Mol Aspects Med. 2008; 29(5):258-89. PMC: 7112278. DOI: 10.1016/j.mam.2008.08.001. View

Takaya H, Yoshiji H, Kawaratani H, Sakai K, Matsumoto M, Fujimura Y . Decreased activity of plasma ADAMTS13 are related to enhanced cytokinemia and endotoxemia in patients with acute liver failure. Biomed Rep. 2017; 7(3):277-285. PMC: 5582607. DOI: 10.3892/br.2017.945. View

Lee M, Rodansky E, Smith J, Rodgers G . ADAMTS13 promotes angiogenesis and modulates VEGF-induced angiogenesis. Microvasc Res. 2012; 84(2):109-15. DOI: 10.1016/j.mvr.2012.05.004. View

Starke R, Ferraro F, Paschalaki K, Dryden N, McKinnon T, Sutton R . Endothelial von Willebrand factor regulates angiogenesis. Blood. 2010; 117(3):1071-80. PMC: 3035068. DOI: 10.1182/blood-2010-01-264507. View

Gish R . Early detection of hepatocellular carcinoma through surveillance using biomarkers. Gastroenterol Hepatol (N Y). 2014; 10(2):121-3. PMC: 4011377. View

Mochizuki S, Okada Y . ADAM28 as a target for human cancers. Curr Pharm Des. 2009; 15(20):2349-58. DOI: 10.2174/138161209788682424. View

Mochizuki S, Soejima K, Shimoda M, Abe H, Sasaki A, Okano H . Effect of ADAM28 on carcinoma cell metastasis by cleavage of von Willebrand factor. J Natl Cancer Inst. 2012; 104(12):906-22. DOI: 10.1093/jnci/djs232. View

Koo B, Oh D, Chung S, Kim N, Park S, Jang Y . Deficiency of von Willebrand factor-cleaving protease activity in the plasma of malignant patients. Thromb Res. 2002; 105(6):471-6. DOI: 10.1016/s0049-3848(02)00053-1. View

10.

Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y . JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. Liver Cancer. 2015; 3(3-4):458-68. PMC: 4531423. DOI: 10.1159/000343875. View

11.

Uemura M, Fujimura Y, Ko S, Matsumoto M, Nakajima Y, Fukui H . Determination of ADAMTS13 and Its Clinical Significance for ADAMTS13 Supplementation Therapy to Improve the Survival of Patients with Decompensated Liver Cirrhosis. Int J Hepatol. 2011; 2011():759047. PMC: 3170842. DOI: 10.4061/2011/759047. View

12.

Nierodzik M, Kajumo F, Karpatkin S . Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo. Cancer Res. 1992; 52(12):3267-72. View

13.

Snyder K, Kessler C . The pivotal role of thrombin in cancer biology and tumorigenesis. Semin Thromb Hemost. 2009; 34(8):734-41. DOI: 10.1055/s-0029-1145255. View

14.

Cheung S, Fan S, Lee Y, Chow J, Ng I, Fong D . Albumin mRNA in plasma predicts post-transplant recurrence of patients with hepatocellular carcinoma. Transplantation. 2008; 85(1):81-7. DOI: 10.1097/01.tp.0000298003.88530.11. View

15.

Kudo M, Hatano E, Ohkawa S, Fujii H, Masumoto A, Furuse J . Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial. J Gastroenterol. 2016; 52(4):494-503. DOI: 10.1007/s00535-016-1247-4. View

16.

Katoh H, Nakamura K, Tanaka T, Satomura S, Matsuura S . Automatic and simultaneous analysis of Lens culinaris agglutinin-reactive alpha-fetoprotein ratio and total alpha-fetoprotein concentration. Anal Chem. 1998; 70(10):2110-4. DOI: 10.1021/ac971280c. View

17.

Lee M, Keener J, Xiao J, Zheng X, Rodgers G . ADAMTS13 and its variants promote angiogenesis via upregulation of VEGF and VEGFR2. Cell Mol Life Sci. 2014; 72(2):349-56. PMC: 11113207. DOI: 10.1007/s00018-014-1667-3. View

18.

. Clinical Practice Guidelines for Hepatocellular Carcinoma Differ between Japan, United States, and Europe. Liver Cancer. 2015; 4(2):85-95. PMC: 4439783. DOI: 10.1159/000367730. View

19.

Tripodi A, Anstee Q, Sogaard K, Primignani M, Valla D . Hypercoagulability in cirrhosis: causes and consequences. J Thromb Haemost. 2011; 9(9):1713-23. DOI: 10.1111/j.1538-7836.2011.04429.x. View

20.

Kobayashi K, Maruyama H, Kiyono S, Ogasawara S, Suzuki E, Ooka Y . Application of transcutaneous ultrasonography for the diagnosis of muscle mass loss in patients with liver cirrhosis. J Gastroenterol. 2017; 53(5):652-659. DOI: 10.1007/s00535-017-1378-2. View